Cellect Biotechnology Ltd. (APOP) surged 56.88% in the after-market session on Wednesday, June 16, 2021, and close the day at $1.86 per share. Earlier in Wednesday’s morning session, APOP stock gained 7.57% and close the morning session at $3.27 per share.
APOP shares have risen 3.48% over the last 12 months, and they have moved up 5.48% in the past week. Over the past three months, the stock has lost 9.67%, while over the past six months, it has added 39.15%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Filing Registration Statement
On June 16, 2021, Cellect Biotechnology Ltd filed a registration statement, including a joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. The transaction is currently expected to close in the 2021 third quarter.
Read More
Top Line data results from Phase 1/2 clinical trial of ApoGraft™ technology
On April 19, 2021, Cellect Biotechnology Ltd reported positive data from the Company’s open-label Phase 1/2 clinical trial of its ApoGraft™ technology in Israel.
All eleven patients in the trial were engrafted promptly by using the ApoGraft product. The primary objective, safety, and tolerability were met and there were no procedure-related adverse events.
Q4 & FY 2020 financial results announcement
On March 29, 2021, Cellect Biotechnology Ltd released its financial and operating results for the fourth quarter and full-year ended December 31, 2020.
Q4 2020 financial highlights
- Research and development (R&D) expenses for the fourth quarter were $0.53 million compared to $0.80 million in Q 4 2019.
- The company suffered a comprehensive loss of $1.58 million or $0.004 per share in Q4 2020 compared to $1.89 million, or $0.008 per share, in the fourth quarter of 2019.
- General and administrative (G&A) expenses for the fourth quarter were $0.67 million compared to $0.74 million in the fourth quarter of 2019.
- Finance expenses for the fourth quarter of 2020 were $0.38 million compared to finance expenses of $0.35 million in the fourth quarter of 2019.
FY 2020 financial highlights
- Research and development (R&D) expenses for the year 2020 were $1.83 million compared to$3.77 million for FY 2019.
- The company suffered a comprehensive loss of $5.62 million or $0.015 per share in FY 2020 compared to $5.23 million, or $0.025 per share, for the full year of 2019.
- General and administrative (G&A) expenses for the full year of 2020 were $2.52 million, compared to $3.18 million for the full year of 2019.
- Financial expenses were $1.27 million for the full year of 2020, compared to financial income of $1.72 million for the full year of 2019.
Conclusion
The filing of the registration statement could be the reason behind its exceptional performance on Wednesday as it can be seen as a major step towards the completion of the announced merger.
